Concepedia

Fc Region Engineering

Fc Region Engineering is a protein modification strategy that involves the targeted alteration of the constant fragment (Fc) region of an antibody to enhance or modulate its effector functions, stability, and pharmacokinetic properties.

65

Publications

5.3K

Citations

500

Authors

160

Institutions

Publications per year

2017–2026

24

Parents

Publications

65

Engineered antibody Fc variants with enhanced effector function

Greg A. Lazar, Wei Dang, Sher Karki et al. · Proceedings of the National Academy of Sciences · 2006 · 794 citations · Full text

, , +17

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

Tilman Schlothauer, Sylvia Herter, Claudia Ferrara et al. · Protein Engineering Design and Selection · 2016 · 419 citations · Full text

, , +17

Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels

Carlos Vaccaro, Jinchun Zhou, Raimund J. Ober et al. · Nature Biotechnology · 2005 · 399 citations

, , +16

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso et al. · JAMA Oncology · 2021 · 349 citations · Full text

, , +17

Reduced elimination of IgG antibodies by engineering the variable region

Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana et al. · Protein Engineering Design and Selection · 2010 · 262 citations

, , +17

1–5 of 65

Authors

500

  1. RJ
    Raimund J. Ober

    The University of Texas Southwestern Medical Center, United States

    3 publications · 523 citations

    3

    h-index

  2. ES
    E. Sally Ward

    The University of Texas Southwestern Medical Center, United States

    3 publications · 523 citations

    3

    h-index

  3. FM
    Futa Mimoto

    Chugai Pharma (United States), United States

    3 publications · 407 citations

    3

    h-index

  4. SI
    Seock‐Ah Im

    Seoul National University Hospital, South Korea

    3 publications · 443 citations

    3

    h-index

  5. SH
    Susan H. Tam

    Janssen (United States), United States

    3 publications · 123 citations

    3

    h-index

1–5 of 500

Institutions

160

  1. The University of Texas Southwestern Medical Center

    Dallas, United States

    5 h-index

    18 publications

    2.8K citations

  2. Xencor (United States)

    Monrovia, United States

    4 h-index

    26 publications

    11.5K citations

  3. Christian-Albrechts-Universität zu Kiel

    Kiel, Germany

    3 h-index

    12 publications

    521 citations

  4. Janssen (United States)

    Hopewell, United States

    3 h-index

    17 publications

    374 citations

  5. Chugai Pharma (United States)

    Berkeley Heights, United States

    3 h-index

    22 publications

    4.2K citations

  6. MacroGenics (United States)

    Rockville, United States

    3 h-index

    14 publications

    2.4K citations

  7. Seoul National University Hospital

    Seoul, South Korea

    3 h-index

    3 publications

    443 citations

  8. European Institute of Oncology

    Milan, Italy

    2 h-index

    2 publications

    429 citations

1–8 of 160

Venues

  1. mAbs

    7 publications · 308 citations

    7

    h-index

  2. Protein Engineering Design and Selection

    PEDS · 4 publications · 823 citations

    4

    h-index

  3. Journal of Clinical Oncology

    3 publications · 125 citations

    3

    h-index

  4. Methods

    2 publications · 86 citations

    2

    h-index

  5. Proceedings of the National Academy of Sciences

    PNAS · 2 publications · 872 citations

    2

    h-index

1–5